Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Lung Cancer

  Free Subscription


Articles published in Lancet Oncol

Retrieve available abstracts of 100 articles:
HTML format



Single Articles


    July 2024
  1. LAZARATOS AM, Petrecca K, Guiot MC, Jerzak KJ, et al
    CNS activity of trastuzumab deruxtecan in HER2-expressing non-small-cell lung cancer.
    Lancet Oncol. 2024;25:e282.
    PubMed    


  2. AERTS JG, Belderbos R, Baas P, Scherpereel A, et al
    Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase
    Lancet Oncol. 2024;25:865-878.
    PubMed     Abstract available


  3. ZAUDERER MG, Dagogo-Jack I
    Refreshing the mesothelioma catalogue: tailoring cellular therapy in the DENIM trial.
    Lancet Oncol. 2024;25:825-827.
    PubMed    


    June 2024
  4. CHEN L, Zhu XZ, Zhao SJ, Yang QW, et al
    PD-L1 as a predictive factor for non-small-cell lung cancer prognosis.
    Lancet Oncol. 2024;25:e233.
    PubMed    


    May 2024
  5. BURKI T
    EPA ruling to ban chrysotile asbestos.
    Lancet Oncol. 2024;25:537.
    PubMed    


    April 2024
  6. SMIT EF, Felip E, Uprety D, Nagasaka M, et al
    Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
    Lancet Oncol. 2024;25:439-454.
    PubMed     Abstract available


    March 2024
  7. GOULART BHL, Mushti SL, Chatterjee S, Larkins E, et al
    Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis.
    Lancet Oncol. 2024 Mar 5:S1470-2045(24)00040.
    PubMed     Abstract available


    February 2024
  8. RHA SY, Bordia S
    Pembrolizumab plus chemotherapy for advanced gastric cancer - Authors' reply.
    Lancet Oncol. 2024;25:e52.
    PubMed    


  9. SCHUTTE T, Derks S, van Laarhoven HWM
    Pembrolizumab plus chemotherapy for advanced gastric cancer.
    Lancet Oncol. 2024;25:e51.
    PubMed    


  10. HUANG CY, Wu XB
    Pembrolizumab plus chemotherapy for advanced gastric cancer.
    Lancet Oncol. 2024;25:e50.
    PubMed    


    January 2024
  11. RASHID T, Bennett JE, Muller DC, Cross AJ, et al
    Mortality from leading cancers in districts of England from 2002 to 2019: a population-based, spatiotemporal study.
    Lancet Oncol. 2024;25:86-98.
    PubMed     Abstract available


    December 2023
  12. LEAL T, Langer C
    Tumor Treating Fields therapy in metastatic non-small-cell lung cancer - Authors' reply.
    Lancet Oncol. 2023;24:e454.
    PubMed    


  13. OLIVIER T, Addeo A
    Tumor Treating Fields therapy in metastatic non-small-cell lung cancer.
    Lancet Oncol. 2023;24:e453.
    PubMed    


  14. FURLOW B
    IASLC calls for clinical trials to use tobacco use data.
    Lancet Oncol. 2023;24:1309.
    PubMed    


    November 2023
  15. SCOTT SE, Gildea C, Nicholson BD, Evans RE, et al
    Future cancer risk after urgent suspected cancer referral in England when cancer is not found: a national cohort study.
    Lancet Oncol. 2023;24:1242-1251.
    PubMed     Abstract available


  16. DOUMA LH, Lalezari F, van der Noort V, de Vries JF, et al
    Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study.
    Lancet Oncol. 2023;24:1219-1228.
    PubMed     Abstract available


    October 2023
  17. COOPER WA
    Lessons and opportunities from improved understanding of global lung cancer histological subtypes.
    Lancet Oncol. 2023 Oct 11:S1470-2045(23)00475.
    PubMed    


  18. ZHANG Y, Vaccarella S, Morgan E, Li M, et al
    Global variations in lung cancer incidence by histological subtype in 2020: a population-based study.
    Lancet Oncol. 2023 Oct 11:S1470-2045(23)00444.
    PubMed     Abstract available


  19. HU X, Wang C, Huang W, Barber SM, et al
    Pembrolizumab monotherapy for advanced chordoma.
    Lancet Oncol. 2023;24:e399.
    PubMed    


    September 2023
  20. FENNELL DA
    Tumor Treating Fields therapy could potentiate immunotherapy in non-small-cell lung cancer.
    Lancet Oncol. 2023;24:946-947.
    PubMed    


  21. LEAL T, Kotecha R, Ramlau R, Zhang L, et al
    Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 st
    Lancet Oncol. 2023;24:1002-1017.
    PubMed     Abstract available


    August 2023
  22. OZGUROGLU M, Kilickap S, Sezer A, Gumus M, et al
    First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 tri
    Lancet Oncol. 2023 Aug 14:S1470-2045(23)00329.
    PubMed     Abstract available


  23. GOURD E
    Middle-age lung screening for everyone who has smoked.
    Lancet Oncol. 2023;24:838.
    PubMed    


    July 2023
  24. JAYAKRISHNAN B, Burney I, Osman AH, Bennji SM, et al
    Adenocarcinoma of lung presenting as diffuse interstitial lung disease.
    Lancet Oncol. 2023;24:e323.
    PubMed    


    May 2023
  25. O'DOWD EL, Lee RW, Akram AR, Bartlett EC, et al
    Defining the road map to a UK national lung cancer screening programme.
    Lancet Oncol. 2023;24:e207-e218.
    PubMed     Abstract available


  26. GHORANI E, Quartagno M, Blackhall F, Gilbert DC, et al
    REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment.
    Lancet Oncol. 2023;24:e219-e227.
    PubMed     Abstract available


    March 2023
  27. MITTAL R, Maikap D, Mishra P, Padhan P, et al
    Sclerotic bone metastasis as initial manifestation of lung adenocarcinoma in a patient with SLE.
    Lancet Oncol. 2023;24:e144.
    PubMed    


    February 2023
  28. DONG YM, Sun SZ, Ding SS, Chen HM, et al
    Pseudoprogression of a cutaneous lung cancer metastasis.
    Lancet Oncol. 2023;24:e102.
    PubMed    


    December 2022
  29. SORSCHER S
    Pembrolizumab as adjuvant therapy in non-small-cell lung cancer.
    Lancet Oncol. 2022;23:e529.
    PubMed    


  30. GANGULY S, Gogia A
    Pembrolizumab as adjuvant therapy in non-small-cell lung cancer.
    Lancet Oncol. 2022;23:e528.
    PubMed    


  31. UPRETY D
    Pembrolizumab as adjuvant therapy in non-small-cell lung cancer.
    Lancet Oncol. 2022;23:e527.
    PubMed    


    November 2022
  32. WESTEEL V, Zalcman G, Scherpereel A, Milleron B, et al
    Thoracic CT follow-up after non-small-cell lung cancer resection - Authors' reply.
    Lancet Oncol. 2022;23:e486.
    PubMed    


  33. GOTO T
    Thoracic CT follow-up after non-small-cell lung cancer resection.
    Lancet Oncol. 2022;23:e485.
    PubMed    


  34. WOODARD GA, Boffa DJ, Blasberg JD
    Thoracic CT follow-up after non-small-cell lung cancer resection.
    Lancet Oncol. 2022;23:e484.
    PubMed    


  35. HEUVELMANS MA, Oudkerk M
    Thoracic CT follow-up after non-small-cell lung cancer resection.
    Lancet Oncol. 2022;23:e483.
    PubMed    


    October 2022
  36. QIN N, Wang C, Chen C, Yang L, et al
    Association of the interaction between mosaic chromosomal alterations and polygenic risk score with the risk of lung cancer: an array-based case-control association and prospective cohort study.
    Lancet Oncol. 2022 Oct 17. pii: S1470-2045(22)00600.
    PubMed     Abstract available


  37. SUBBIAH V, Wolf J, Konda B, Kang H, et al
    Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
    Lancet Oncol. 2022;23:1261-1273.
    PubMed     Abstract available


    September 2022
  38. GOURD E
    New evidence that air pollution contributes substantially to lung cancer.
    Lancet Oncol. 2022 Sep 15. pii: S1470-2045(22)00569.
    PubMed    


  39. O'BRIEN M, Paz-Ares L, Marreaud S, Dafni U, et al
    Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
    Lancet Oncol. 2022 Sep 9. pii: S1470-2045(22)00518.
    PubMed     Abstract available


    August 2022
  40. WESTEEL V, Foucher P, Scherpereel A, Domas J, et al
    Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial.
    Lancet Oncol. 2022 Aug 11. pii: S1470-2045(22)00451.
    PubMed     Abstract available


  41. NESTLE U, Delorme S
    What is the best choice of follow-up procedure following resection of lung cancer?
    Lancet Oncol. 2022 Aug 11. pii: S1470-2045(22)00499.
    PubMed    


  42. GERALDES FO
    IASLC 2022 World Conference on Lung Cancer.
    Lancet Oncol. 2022 Aug 11. pii: S1470-2045(22)00510.
    PubMed    


    July 2022
  43. ELKRIEF A, Yu H
    Combination regimens in EGFR-mutated lung cancer: can we get ORIENT-ed?
    Lancet Oncol. 2022 Jul 28. pii: S1470-2045(22)00449.
    PubMed    


  44. LU S, Wu L, Jian H, Chen Y, et al
    Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double
    Lancet Oncol. 2022 Jul 28. pii: S1470-2045(22)00382.
    PubMed     Abstract available


  45. SILVA V, Abrao F, Peres S, Rosamilia G, et al
    Prognostic factors in curative intent stage I lung adenocarcinoma: a retrospective hospital-based cohort study.
    Lancet Oncol. 2022;23 Suppl 1:S31.
    PubMed     Abstract available


  46. LAYCOCK A, Taylor O, Boardman G, Bentel J, et al
    Discordance between clinical and post-surgical staging of patients with operable non-small cell lung cancer: a retrospective audit of lung cancer surgery with curative intent from a single pathology practice.
    Lancet Oncol. 2022;23 Suppl 1:S24.
    PubMed     Abstract available


  47. ZHENG X, Lu T, Wu S, Peng W, et al
    Tumour response heterogeneity as a powerful independent predictor of treatment outcome in advanced lung adenocarcinoma: a retrospective analysis.
    Lancet Oncol. 2022;23 Suppl 1:S13.
    PubMed     Abstract available


    June 2022
  48. RECONDO G, Mezquita L
    Tiragolumab and atezolizumab in patients with PD-L1 positive non-small-cell lung cancer.
    Lancet Oncol. 2022;23:695-697.
    PubMed    


  49. ANDRE T, Diaz LA Jr, Shiu KK
    Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy - Authors' reply.
    Lancet Oncol. 2022;23:e246.
    PubMed    


  50. BOMZE D, Mutti L, Goldman A, Markel G, et al
    Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy.
    Lancet Oncol. 2022;23:e245.
    PubMed    


  51. FENNELL DA, Nusrat N
    Abemaciclib for malignant pleural mesothelioma - Authors' reply.
    Lancet Oncol. 2022;23:e238.
    PubMed    


  52. NARDONE V, Porta C, Giannicola R, Correale P, et al
    Abemaciclib for malignant pleural mesothelioma.
    Lancet Oncol. 2022;23:e237.
    PubMed    


  53. ZAUDERER MG, Szlosarek PW, Le Moulec S, Popat S, et al
    EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study.
    Lancet Oncol. 2022;23:758-767.
    PubMed     Abstract available


    May 2022
  54. GAEBE K, Li AY, Park A, Parmar A, et al
    Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis.
    Lancet Oncol. 2022 May 26. pii: S1470-2045(22)00271.
    PubMed     Abstract available


  55. RIEKEN S
    Stereotactic radiosurgery for patients with small-cell lung cancer brain metastases.
    Lancet Oncol. 2022 May 26. pii: S1470-2045(22)00301.
    PubMed    


  56. SMITH KER, Mansfield AS
    Validating chemoimmunotherapy in small-cell lung cancer.
    Lancet Oncol. 2022 May 13. pii: S1470-2045(22)00288.
    PubMed    


  57. CHO BC, Abreu DR, Hussein M, Cobo M, et al
    Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
    Lancet Oncol. 2022 May 13. pii: S1470-2045(22)00226.
    PubMed     Abstract available


  58. WANG J, Zhou C, Yao W, Wang Q, et al
    Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2022 May 13. pii: S1470-2045(22)00224.
    PubMed     Abstract available


    April 2022
  59. WU YL
    Sequential chemoradiotherapy followed by sugemalimab for locally advanced NSCLC - Author's reply.
    Lancet Oncol. 2022;23:e159.
    PubMed    


  60. BI N, Wang Y, Wang L
    Sequential chemoradiotherapy followed by sugemalimab for locally advanced NSCLC.
    Lancet Oncol. 2022;23:e158.
    PubMed    


  61. OCHOA-DE-OLZA M, Bourhis J, Coukos G, Herrera FG, et al
    Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC.
    Lancet Oncol. 2022;23:e157.
    PubMed    


  62. CHANG JY, Verma V, Welsh JW, Formenti SC, et al
    Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC.
    Lancet Oncol. 2022;23:e156.
    PubMed    


  63. KINDLER HL, Novello S, Bearz A, Ceresoli GL, et al
    Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.
    Lancet Oncol. 2022;23:540-552.
    PubMed     Abstract available


  64. OTTAIANO A, Santorsola M, Caraco F, Caraglia M, et al
    Initial tumour burden and hidden oligometastatic disease in phase 3 clinical trials.
    Lancet Oncol. 2022;23:452-454.
    PubMed    


  65. ZAUDERER MG, Offin M
    ARCS-M: forging progress from this negative trial in malignant pleural mesothelioma.
    Lancet Oncol. 2022;23:445-446.
    PubMed    


    March 2022
  66. FENNELL DA, King A, Mohammed S, Greystoke A, et al
    Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.
    Lancet Oncol. 2022;23:374-381.
    PubMed     Abstract available


    February 2022
  67. MACMANUS M, Hegi-Johnson F
    Overcoming immunotherapy resistance in NSCLC.
    Lancet Oncol. 2022;23:191-193.
    PubMed    


    January 2022
  68. ZHOU C, Wang Z, Sun Y, Cao L, et al
    Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.
    Lancet Oncol. 2022 Jan 14. pii: S1470-2045(21)00650.
    PubMed     Abstract available


  69. ROSELL R, Cao P
    Promising outlook with sugemalimab in non-small-cell lung cancer.
    Lancet Oncol. 2022 Jan 14. pii: S1470-2045(21)00698.
    PubMed    


  70. ZHOU Q, Chen M, Jiang O, Pan Y, et al
    Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phas
    Lancet Oncol. 2022 Jan 14. pii: S1470-2045(21)00630.
    PubMed     Abstract available


  71. SCHOENFELD JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, et al
    Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
    Lancet Oncol. 2022 Jan 13. pii: S1470-2045(21)00658.
    PubMed     Abstract available


  72. FENNELL DA, Griffiths G, Ottensmeier C, Hanna GG, et al
    CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - Authors' reply.
    Lancet Oncol. 2022;23:e14-e15.
    PubMed    


  73. CORREALE P, Pentimalli F, Nardone V, Giordano A, et al
    CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma?
    Lancet Oncol. 2022;23:e13.
    PubMed    


    December 2021
  74. LE PECHOUX C, Pourel N, Barlesi F, Lerouge D, et al
    Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial.
    Lancet Oncol. 2021 Dec 14. pii: S1470-2045(21)00606.
    PubMed     Abstract available


  75. HENDRIKS LEL, De Ruysscher DKM
    Postoperative radiotherapy in resected N2 non-small-cell lung cancer: Lung ART.
    Lancet Oncol. 2021 Dec 14. pii: S1470-2045(21)00654.
    PubMed    


  76. PFEIFFER P, Qvortrup C
    KRAS(G12C) inhibition in colorectal cancer.
    Lancet Oncol. 2021 Dec 14. pii: S1470-2045(21)00652.
    PubMed    


  77. TAMMEMAGI MC, Ruparel M, Tremblay A, Myers R, et al
    USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study.
    Lancet Oncol. 2021 Dec 10. pii: S1470-2045(21)00590.
    PubMed     Abstract available


  78. TEN HAAF K
    Risk-based lung cancer screening eligibility criteria: towards implementation.
    Lancet Oncol. 2021 Dec 10. pii: S1470-2045(21)00636.
    PubMed    


  79. WILKINSON E
    COVID-19 pandemic to lead to thousands of additional UK lung cancer deaths.
    Lancet Oncol. 2021 Dec 2. pii: S1470-2045(21)00699.
    PubMed    


  80. CHANG JY, Verma V, Feng L, Roth JA, et al
    SABR for operable stage I non-small-cell lung cancer: comparison to surgery - Authors' reply.
    Lancet Oncol. 2021;22:e537-e538.
    PubMed    


  81. ZHANG J, Liu L, Zhao K, Guo C, et al
    SABR for operable stage I non-small-cell lung cancer: comparison to surgery.
    Lancet Oncol. 2021;22:e536.
    PubMed    


  82. LUO MS
    SABR for operable stage I non-small-cell lung cancer: comparison to surgery.
    Lancet Oncol. 2021;22:e535.
    PubMed    


  83. KASHIHARA T
    SABR for operable stage I non-small-cell lung cancer: comparison to surgery.
    Lancet Oncol. 2021;22:e534.
    PubMed    


  84. ZUCALI PA, Pinto C, Ceresoli GL
    RAMES study: is there really a role for VEGF inhibition in mesothelioma? - Authors' reply.
    Lancet Oncol. 2021;22:e533.
    PubMed    


  85. PORTA C, Nardone V, Gray SG, Correale P, et al
    RAMES study: is there really a role for VEGF inhibition in mesothelioma?
    Lancet Oncol. 2021;22:e532.
    PubMed    


    November 2021
  86. SAW SPL, Ong BH, Chua KLM, Takano A, et al
    Revisiting neoadjuvant therapy in non-small-cell lung cancer.
    Lancet Oncol. 2021;22:e501-e516.
    PubMed     Abstract available


  87. FENNELL DA, Ewings S, Ottensmeier C, Califano R, et al
    Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
    Lancet Oncol. 2021;22:1530-1540.
    PubMed     Abstract available


    October 2021
  88. KINDLER HL
    Understanding the new therapeutic options for mesothelioma.
    Lancet Oncol. 2021;22:1353-1355.
    PubMed    


  89. PINTO C, Zucali PA, Pagano M, Grosso F, et al
    Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet Oncol. 2021;22:1438-1447.
    PubMed     Abstract available


    September 2021
  90. LANDMAN A
    2021 World Conference on Lung Cancer.
    Lancet Oncol. 2021 Sep 16. pii: S1470-2045(21)00547.
    PubMed    


  91. CHANG JY, Mehran RJ, Feng L, Verma V, et al
    Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery.
    Lancet Oncol. 2021 Sep 13. pii: S1470-2045(21)00401.
    PubMed     Abstract available


  92. LOUIE AV, Tjong MC, Siva S
    Surgery versus SABR for early-stage lung cancer-time to call it a draw?
    Lancet Oncol. 2021 Sep 13. pii: S1470-2045(21)00457.
    PubMed    


  93. BURKI TK
    Developments in lung cancer biology in never-smokers.
    Lancet Oncol. 2021 Sep 9. pii: S1470-2045(21)00532.
    PubMed    


    August 2021
  94. HUYNH C, Sorin M, Rayes R, Fiset PO, et al
    Pathological complete response as a surrogate endpoint after neoadjuvant therapy for lung cancer.
    Lancet Oncol. 2021;22:1056-1058.
    PubMed    


    June 2021
  95. GAINOR JF, Curigliano G, Kim DW, Lee DH, et al
    Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
    Lancet Oncol. 2021 Jun 9. pii: S1470-2045(21)00247.
    PubMed     Abstract available


  96. GRONBERG BH, Langer SW, Nyman J, Halvorsen TO, et al
    Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer - Authors' reply.
    Lancet Oncol. 2021;22:e222.
    PubMed    


  97. XIE L, Fan X, Qian B
    Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer.
    Lancet Oncol. 2021;22:e221.
    PubMed    


  98. LEVY A, Le Pechoux C, Faivre-Finn C
    Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer.
    Lancet Oncol. 2021;22:e220.
    PubMed    


    May 2021
  99. ALTORKI NK, McGraw TE, Borczuk AC, Saxena A, et al
    Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.
    Lancet Oncol. 2021 May 17. pii: S1470-2045(21)00149.
    PubMed     Abstract available


  100. SEPESI B, Cascone T
    Will radiotherapy be a future part of neoadjuvant therapy in operable non-small-cell lung cancer?
    Lancet Oncol. 2021 May 17. pii: S1470-2045(21)00261.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.